HIV-Positive Patients Faced Longer CAR-T Travel Times
New research shows that cancer patients living with HIV often face significant geographic barriers to clinical trial access.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Should federal healthcare policy prioritize expanding clinical trial access in underserved geographic regions?
A study of 80 CAR-T clinical trials found that patients living with HIV must travel significantly farther to reach inclusive centers than those in non-inclusive trials. This disparity is particularly pronounced in the US South, where geographic and systemic barriers restrict access to emerging cancer therapies.
Why it matters
Understanding these inequities is critical as CAR-T therapies become more prevalent, as geographic distance acts as a major gatekeeper for patients needing life-saving care. The data highlights how restrictive trial criteria disproportionately burden vulnerable populations.
Researchers found that only 13.8 percent of analyzed CAR-T trials include people living with HIV, while 72.5 percent explicitly exclude them. HIV-positive patients in the US South face a median travel time of 1.70 hours compared to 0.92 hours for other participants.
The players
National Institutes of Health
This federal agency maintains the clinical trials database that researchers surveyed to assess accessibility for NHL CAR-T therapies.
The details
Using geospatial mapping, researchers analyzed 80 interventional CAR-T trials across the United States to measure accessibility. The study identified that lower household income consistently correlates with longer travel times, further compounded by trial requirements that limit inclusivity for HIV-positive individuals.
Timeline
Study findings on CAR-T access were published on September 30, 2026.
The Big Picture
This study follows a pattern set by the historical trend of HIV-based exclusion in clinical trials. The findings highlight a systemic departure from modern medical inclusivity, documenting how legacy trial protocols continue to shape patient access in the era of advanced immunotherapy.
Patients living with HIV may need to plan for longer travel times and additional transit costs when seeking participation in CAR-T clinical trials. These geographic findings suggest that access to specialized oncology centers remains a significant challenge for equitable healthcare delivery.
The takeaway
Patients should discuss travel support options and trial site locations with their oncology teams early in the treatment planning process. Removing exclusionary criteria from future clinical trials is essential to ensure that geographic distance does not dictate a patient's survival.
Further reading
Learn more about evolving standards in Cancer research and patient care.
Source note: This article includes information reported by Notre Dame News.
Live Poll
Should federal healthcare policy prioritize expanding clinical trial access in underserved geographic regions?
